Dr. Amy Paller shares her opinion on the need for treatment with biologics of children with atopic dermatitis. She highlights that children with moderate-to-severe disease have the greatest risk of persistance, and that they have a high disease burden. She notes that advanced systemic therapies with a good safety profile are available or under evaluation, and that early intervention may help to change the course of disease.
Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US
See author’s profile